The company has multiple medical cannabis research partners across the world.

Zelda is focused on developing a range of cannabinoid-based formulations

( ) has appointed experienced drug developer Dr Richard Hopkins as its managing director, effective today.

Dr Hopkins brings extensive knowledge and experience with his established track record in drug development of novel cancer therapies.

He also has strong experience with corporate strategy, business development and intellectual property matters.

Strategic focus on clinical validation of medicinal cannabis

Zelda’s new managing director Dr Richard Hopkins said: “I am excited to be joining Zelda Therapeutics at such a key point in the company’s development.

“I look forward to adding value to Zelda’s strategic direction and in particular leveraging revenue opportunities from the current clinical programs in the fast-growing medicinal cannabis sector.”

Zelda is an Australian-based bio-pharmaceutical company that is focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions.

The company has a two-pronged strategy comprising:

• A human clinical trial programme focused on insomnia, autism and eczema with activities in Australia, Chile and the US; and

• A pre-clinical research program examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.